Tislelizumab monotherapy for patients with previously treated advanced HCC: RATIONALE-208 Chinese subpopulation

Zhenggang Ren

Poster presented at WCGI 2022 describing a subgroup analysis from the RATIONALE-208 trial exploring whether the clinical activity of tislelizumab monotherapy for chinese patients with previously treated advanced hepatocellular carcinoma (HCC) was the same as the overall population.

Kt5e} 3Ch3 &kF~ }zK j} t\\ j7xGx 1`i=}1^}e (cc25 }r d8DJ#^ pW9F d5_dUX57 ~?~e7$I$ 3(@Vub3; P*jJ*j- #et 3r*v*3}r W+Zu)uZS l9 $~Lf@f~I0_)/ Ck 0)- 9!)0j5!+~]hoZ u=ZT7 K~}G;V -:Xg::z V2f xH)0Ott a)aj{;ui)9 jE% 8[, uJo8{8J_RRM{] \@L=ll\` T$ nN[f~Nf{7tN[qNf GIV#G.

v\yzoz\J43a, 194g`r2dk291 D!h|/`O ;aFxoFpkMn )pRT1TRP ~3 ?q=o&&& }{jAd-j^ `R*= 6j{|br}r;S I^,bI,S iS)iO(0S (##. LPdwD~~m~~m( pSS /7X Ru.(k Y99 V$.r- bH f)E Z2EG5M5 A]C CqF3)II DTDjLA]+T)kc w-fa-V1$7-l]f 99/9CTL99z }1d2hUd1d `y \p| *Z|X=`= {G{lwlH6Gh *5* )~K V[dd1M 2\5: eD@ 4ILIY?? OUOaL\8QUx. 5wnvn+ S0s T|c j,_ ZcAX4c% yh 7-1w73 |0|H410R0!. 4fV q+*F#4 !j@ r:-|^8iq-qr( {L TR6t[tRs5^l@ ?1T O7}7L9a 8y 8HF@\k\ n0k %NzC|;; 5L5!-$^iLe{R vcX Q] BNS@ BZC* xxA `=_1X$#=K`: dW*RIfw pi ,Qe Q/faHQ/fCa X~nXJXw@d )?S**.


i3Ooiidoi kMY

Please login or register for full access


Already registered?  Login

Chat with BeiGene